Sep 2026· Journal of Clinical and Diagnostic Research· 0 citations
TL;DR
The need for a proactive, integrated approach which combines medical, public health and scientific efforts for the mitigation of the threat of NiV globally is underscored.
Abstract
Nipah virus (NiV) is known to be an emerging zoonotic pathogen of the Paramyxoviridae family, which was first identified in 1998, and is also associated with high morbidity and mortality due to severe encephalitis and respiratory illness. Transmission occurs through direct contact with infected animals, contaminated food, and human-to-human transmission , thereby further highlighting its epidemic potential. Despite significant advances in understanding its virology, pathogenesis, as well as clinical manifestations, NiV outbreaks continue to pose substantial public health challenges, usually in endemic regions. Current management of NiV remains largely supportive with no licensed antivirals or vaccines available, thus emphasising the need for effective medical countermeasures. Recent therapeutic developments must focus on monoclonal antibodies and antiviral agents, including Remdesivir, which have shown promising efficacy in preclinical studies. Vaccine candidates, including recombinant protein, viral vector, and mRNA-based platforms, are being examined in their early phases of clinical evaluation, showing potential for robust protection of immunity. Future research priorities must include the development of rapid point-of-care diagnosis, strengthening genomic surveillance while also implementing One Health approaches integrating human, animal and environmental data for the prevention of spillover events. Refining animal models and elucidating immune correlates of protection are very important aspects for translating preclinical successes into adequately licensed interventions for management approaches for NiV. Collaborative international frameworks as well as structured R&D roadmaps are critical options for the acceleration of vaccine and therapeutic development, thereby further ensuring rapid deployment during outbreaks. This narrative review article highlights current knowledge on the epidemiology of NiV, pathogenesis, clinical management, as well as emerging preventive-therapeutic strategies while also identifying critical research gaps. It underscores the need for a proactive, integrated approach which combines medical, public health and scientific efforts for the mitigation of the threat of NiV globally.
Overall, continued advances in translational vaccinology, computational vaccine design, and global preparedness may accelerate the development of NiV vaccines.
S. Chatterjee, Joydeep Mahata, Athika Firdous et al.· Frontiers in Drug Discovery· 1 citation
An extremely dangerous zoonotic virus, the Nipah virus (NiV) belonging to the genus Henipavirus and family Paramyxoviridae continues to be a major threat to the world health. Recurrent outbreaks of NiV have been marked by high case fatality rates, severe neurological and respiratory illness, and a lack of effective tre...
Tejaswi Puvvadi, Lakshmi Krishnasamy· IP International Journal of...· 0 citations
Monkeypox virus (MPXV) is an ongoing global public health concern. Historically associated with zoonotic infection, in 2022, a major epidemiological shift occurred when sustained transmission was identified across multiple countries that previously had not had endemic circulation of the virus. While mpox typically pres...
Lisumi Hewa Ranchigoda Kankanamge, Amal Remtulla, Maedeh Naghibosadat et al.· Viruses· 0 citations
Hantavirus is considered as a fatal zoonotic pathogen that can be commonly transmitted from rodents to humans. However, the Andes virus (ANDV), a type of New World hantavirus, can also be transmitted from human to human. It is the cause of the 2026 hantavirus outbreak on a cruise ship. Hantavirus can rapidly progress t...
Parisa Ghasemiyeh, S. Mohammadi-Samani· Virology Journal· 0 citations
Understanding the molecular mechanism and the role of host factors in NiV neuropathogenesis is crucial for developing effective strategies to combat NVD, as well as advancements in therapeutic modalities and vaccines against NVD.
Current evidence on the epidemiology, clinical presentation, diagnostic challenges, and prevention of selected arboviral infections in children within the European context are summarized, highlighting persistent gaps in pediatric-specific data and implications for preparedness and public health.
G. Sturniolo, Silvia Garattini, Denis Doni et al.· Viruses· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.